MRX Related Earnings News
-
Low Visibility Prompts Canaccord to Cut Price Target on Medicis (MRX)
-
Goldman Sach Cuts Price Target on Medicis (MRX)
-
Medicis Pharmaceutical Corp. (MRX) Tops Q2 EPS by 6c; Issues Light Q3, FY12 Outlook
-
Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
-
Auriga Reiterates a 'Buy' on Medicis (MRX); Q1 Beat Underscores Execution
-
Medicis Pharmaceutical Corp. (MRX) Tops Q1 EPS by 18c
-
Needham & Company Reiterates a 'Buy' on Solta Medical (SLTM); Good Quarter
-
Cantor Fitzgerald Maintains a 'Hold' on Medicis (MRX); Adjusting Numbers
-
Canaccord Genuity Maintains a 'Hold' on Medicis (MRX); Taking A Deeper Look
-
Goldman Sachs Upgrades Medicis (MRX) to Buy, Focused on Growth
-
Cantor Fitzgerald Raises Price Target on Medicis (MRX) But Remains Concerned
-
Medicis Pharmaceutical Corp. (MRX) Reports Slightly Better-Than-Expected Q4 Results
-
Medicis (MRX) Guides Q4, FY11 Revs and EPS Below Views; Makes SOLODYN Progress
-
Medicis (MRX) Announces Completion of Graceway Pharmaceuticals Acquisition, Offers Q4, FY11 Guidance
-
Medicis Pharmaceutical Corp. (MRX) Misses Q3 EPS by 5c; Guides Q4 EPS Below Views
-
Medicis Pharmaceutical Corp. (MRX) Reports In-Line Q2 EPS of 64c
-
Medicis Pharmaceutical Corp (MRX) Tops Q1 EPS by 1c; Issues Outlook
-
Medicis Pharma (MRX) Reports In-Line Q4 EPS of 60c; Guides Q1
-
Medicis Pharma (MRX) Posts Q3 non-GAAP EPS of $0.58, Tops by 1c; Guides Q410, FY10 EPS, Revs
-
Medicis Pharma (MRX) Tops Q2 Views; Guides Q3, Q4
-
Medicis Pharma (MRX) Posts Q1 adj.-EPS of $0.54, Tops by 7c; Guides Q210 and FY10 EPS and Revs
-
Medicis (MRX) Tops Q1 EPS by 11c; Guides
-
Medicis Pharmaceutical (MRX) Tops Q4 EPS by 8c; Guides
-
Medicis (MRX) Reports Q3 EPS of $0.50, Beats by 8c; Guides Q4
-
Medicis (MRX) Tops Q2 View By 11c; Guides Higher
-
Medicis (MRX) Reports Q4 Earnings; Guides Q1, Q2, Q3, Q4
-
Medicis (MRX) Reports Q3 Adj-EPS of $0.27, Beats by 5c
-
Medicis (MRX) Beats By 5c; Issues Guidance
-
Medicis (MRX) Adjusts Q3, Q4 and FY08 EPS to Account for LipoSonix Acquisition
-
Medicis (MRX) Tops Q1 View By 4c; Guides Q2
-
Medicis (MRX) Reports Strong Q4 Earnings
-
Medicis (MRX) Reports Q3 EPS
-
Medicis (MRX) Tops Q2 EPS by 3c, Issues Guidance for Q3 and FY
-
Medicis Pharma (MRX) Tops Q1 EPS by 3c, Issues Mixed Guidance for Q2
-
Medicis (MRX) Reports Q4 Results
-
Medicis (MRX) Tops Q3 View; Guides
-
Medicis (MRX) Tops Q3 Views; Guides Above
-
Medicis (MRX) Reports Q1 EPS of $0.20
-
Earning Due Out After The Close Today And Before The Open Tomorrow
-
MRX Reports Q4 Results; Guides
-
MRX Beat Q4 EPS by 2 Cents
-
MRX In-line with Q3 EPS
Back to MRX Stock Lookup
